Stock Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) was the target of some unusual options trading on Friday. Stock traders bought 170,441 call options on the company. This is an increase of approximately 455% compared to the average volume of 30,710 call options.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $119.05 on Friday. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The company has a 50-day simple moving average of $116.55 and a two-hundred day simple moving average of $113.23. The firm has a market capitalization of $294.04 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Barclays started coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective on the stock. Finally, Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $128.18.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Merck & Co., Inc. by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares during the period. State Street Corp grew its position in Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after purchasing an additional 1,859,990 shares during the period. Wellington Management Group LLP grew its position in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the period. Geode Capital Management LLC grew its position in Merck & Co., Inc. by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, DLD Asset Management LP grew its position in Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.